Boehringer’s Nerandomilast Hits Primary Endpoint in Phase III FIBRONEER-ILD for Pulmonary Fibrosis Read more
Novartis Strengthens Cardiovascular Pipeline with $925 Million Anthos Therapeutics Acquisition Read more